ASRT

Company Overview — What Does Assertio Holdings, Inc. Do?

Assertio Holdings, Inc., a specialty pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides CAMBIA, a non-steroidal anti-inflammatory drug (NSAID) for the treatment of migraine, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate acute pain; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat adults with severe, active rheumatoid arthritis, and children with active polyarticular juvenile idiopathic arthritis. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 1995 and is headquartered in Lake Forest, Illinois. Assertio Holdings, Inc. (ASRT) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Daniel A. Peisert and employs approximately 20 people. With a market capitalization of $128M, ASRT is one of the notable companies in the Healthcare sector.

Assertio Holdings, Inc. (ASRT) Stock Rating — Hold (April 2026)

As of April 2026, Assertio Holdings, Inc. receives a Hold rating with a composite score of 36.7/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.ASRT ranks #1,318 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Assertio Holdings, Inc. ranks #103 of 838 stocks, placing it in the top quartile of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

ASRT Stock Price and 52-Week Range

Assertio Holdings, Inc. (ASRT) currently trades at $18.04. The stock gained $0.02 (0.1%) in the most recent trading session. The 52-week high for ASRT is $13.83, which means the stock is currently trading 30.4% from its annual peak. The 52-week low is $0.51, putting the stock 3410.8% above its annual trough. Recent trading volume was 127K shares, suggesting relatively thin trading activity.

Is ASRT Overvalued or Undervalued? — Valuation Analysis

Assertio Holdings, Inc. (ASRT) carries a value factor score of 20/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The trailing price-to-earnings ratio is 96.83x, compared to the Healthcare sector average of 23.63x — a premium of 310%. The price-to-book ratio stands at 1.28x, versus the sector average of 2.75x. The price-to-sales ratio is 0.89x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, ASRT trades at 1.61x EV/EBITDA, versus 6.34x for the sector.

At current multiples, Assertio Holdings, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Assertio Holdings, Inc. Profitability — ROE, Margins, and Quality Score

Assertio Holdings, Inc. (ASRT) earns a quality factor score of 25/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -22.7%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -8.0% versus the sector average of -33.1%.

On a margin basis, Assertio Holdings, Inc. reports gross margins of 68.2%, compared to 71.5% for the sector. The operating margin is -16.2% (sector: -66.1%). Net profit margin stands at -23.5%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 58.9% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

ASRT Debt, Balance Sheet, and Financial Health

Assertio Holdings, Inc. has a debt-to-equity ratio of 184.0%, compared to the Healthcare sector average of 32.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 1.70x, suggesting adequate working capital coverage. Total debt on the balance sheet is $40M. Cash and equivalents stand at $39M.

ASRT has a beta of 1.03, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for Assertio Holdings, Inc. is 34/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Assertio Holdings, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Assertio Holdings, Inc. reported revenue of $134M and earnings per share (EPS) of $-4.74. Net income for the quarter was $-21M. Gross margin was 68.2%. Operating income came in at $-13M.

In FY 2025, Assertio Holdings, Inc. reported revenue of $119M and earnings per share (EPS) of $-4.74. Net income for the quarter was $-30M. Revenue grew -5.0% year-over-year compared to FY 2024. Operating income came in at $-22M.

In Q3 2025, Assertio Holdings, Inc. reported revenue of $49M and earnings per share (EPS) of $0.12. Net income for the quarter was $11M. Revenue grew 69.4% year-over-year compared to Q3 2024. Operating income came in at $11M.

In Q2 2025, Assertio Holdings, Inc. reported revenue of $29M and earnings per share (EPS) of $-0.17. Net income for the quarter was $-16M. Revenue grew -6.1% year-over-year compared to Q2 2024. Operating income came in at $-8M.

Over the past 8 quarters, Assertio Holdings, Inc. has demonstrated a growth trajectory, with revenue expanding from $31M to $134M. Investors analyzing ASRT stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

ASRT Dividend Yield and Income Analysis

Assertio Holdings, Inc. (ASRT) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

ASRT Momentum and Technical Analysis Profile

Assertio Holdings, Inc. (ASRT) has a momentum factor score of 80/100, indicating strong price momentum with the stock outperforming the majority of the market over recent periods. Stocks with high momentum scores have historically tended to continue their outperformance in the near term. The investment factor score is 22/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 5/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

ASRT vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Assertio Holdings, Inc. (ASRT) ranks #103 out of 838 stocks based on the Blank Capital composite score. This places ASRT in the top quartile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing ASRT against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full ASRT vs S&P 500 (SPY) comparison to assess how Assertio Holdings, Inc. stacks up against the broader market across all factor dimensions.

ASRT Next Earnings Date

No upcoming earnings date has been announced for Assertio Holdings, Inc. (ASRT) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy ASRT? — Investment Thesis Summary

Assertio Holdings, Inc. presents a balanced picture with arguments on both sides. The quality score of 25/100 flags below-average profitability. The value score of 20/100 indicates premium valuation. Price momentum is positive at 80/100, suggesting the trend favors buyers. High volatility (stability score 34/100) increases portfolio risk.

In summary, Assertio Holdings, Inc. (ASRT) earns a Hold rating with a composite score of 36.7/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on ASRT stock.

Related Resources for ASRT Investors

Explore more research and tools: ASRT vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare ASRT head-to-head with peers: ASRT vs AZN, ASRT vs SLGL, ASRT vs VMD.